Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies

被引：78

作者：

Kopylov, Uri ^{[1
,2
]}

Mazor, Yoav ^{[3
,4
]}

Yavzori, Miri ^{[1
,2
]}

Fudim, Ella ^{[1
,2
]}

Katz, Lior ^{[1
,2
]}

Coscas, Daniel ^{[1
,2
]}

Picard, Orit ^{[1
,2
]}

Chowers, Yehuda ^{[3
,4
]}

Eliakim, Rami ^{[1
,2
]}

Ben-Horin, Shomron ^{[1
,2
]}

机构：

[1] Chaim Sheba Med Ctr, Dept Gastroenterol, IL-52621 Tel Hashomer, Israel

[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel

[3] Dept Gastroenterol, Haifa, Israel

[4] Technion Israel Inst Technol, Bruce & Ruth Rappaport Sch Med, IL-32000 Haifa, Israel

来源：

INFLAMMATORY BOWEL DISEASES | 2012年 / 18卷 / 09期

关键词：

Crohn's disease; ulcerative colitis; anti-TNF antibodies; infliximab; anti-infliximab antibodies; CROHNS-DISEASE; EFFICACY; THERAPY;

D O I：

10.1002/ibd.21919

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Anti-infliximab antibodies (ATIs) are associated with lower serum infliximab (IFX) trough levels and diminished clinical response. The current most prevalent method for detection of ATI is a double-antigen (DA) enzyme-linked immunosorbent assay (ELISA) utilizing IFX for ligand and detection antibody. Serum IFX interferes with ATI measurement in this method. An alternative ELISA using antihuman lambda chain (AHLC) antibody for ATI detection may be less amenable to this interference. The aim of our study was to compare the performance of AHLC-ATI versus DA-ATI for prediction of clinical response and evaluate the clinical significance of positive ATI in the presence of detectable IFX levels in IFX-treated inflammatory bowel disease (IBD) patients. Methods: In all, 63 patients' sera were analyzed for IFX levels and antibody levels by AHLC and DA. The results were compared with the clinical response to IFX. Percentage of patients with IFX+ATI+ status among IFX-treated patients and the clinical outcome of IFX+ATI+ patients were assessed. Results: ATIs were demonstrated in 22/63 (34.9%) and 18/63 (28.5%) sera of patients by AHLC and DA assay, respectively (P = 0.6). Detectable ATI and in IFX was detected in four patients (6.3%) by AHLC but not by DA assay. IFX+ATI+ status was documented in 8.7% of available sera and was associated with a trend for loss of response. Conclusions: AHLC and DA ELISA are equally effective for ATI detection in patients with undetectable serum IFX. AHLC ELISA detects ATI in some patients with detectable serum IFX. This IFX+ATI+ status may be a harbinger of evolving loss of response to the drug. (Inflamm Bowel Dis 2012)

引用

页码：1628 / 1633

页数：6

共 14 条

[1] Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease [J].

Ainsworth, Mark A. ;

Bendtzen, Klaus ;

Brynskov, Jorn .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (04) :944-948

[2] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[3] Review article: loss of response to anti-TNF treatments in Crohn's disease [J].

Ben-Horin, S. ;

Chowers, Y. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (09) :987-995

[4] The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful [J].

Ben-Horin, Shomron ;

Yavzori, Miri ;

Katz, Lior ;

Kopylov, Uri ;

Picard, Orit ;

Fudim, Ella ;

Coscas, Daniel ;

Bar-Meir, Simon ;

Goldstein, Itamar ;

Chowers, Yehuda .

GUT, 2011, 60 (01) :41-48

[5] Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. [J].

Colombel, Jean Frederic ;

Sandborn, William J. ;

Reinisch, Walter ;

Mantzaris, Gerassimos J. ;

Kornbluth, Asher ;

Rachmilewitz, Daniel ;

Lichtiger, Simon ;

D'Haens, Geert ;

Diamond, Robert H. ;

Broussard, Delma L. ;

Tang, Kezhen L. ;

van der Woude, C. Janneke ;

Rutgeerts, Paul .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (15) :1383-1395

[6] Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review [J].

Gisbert, Javier P. ;

Panes, Julian .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (03) :760-767

[7] Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].

Hanauer, SB ;

Feagan, BG ;

Lichtenstein, GR ;

Mayer, LF ;

Schreiber, S ;

Colombel, JF ;

Rachmilewitz, D ;

Wolf, DC ;

Olson, A ;

Bao, WH ;

Rutgeerts, P .

LANCET, 2002, 359 (9317) :1541-1549

[8] Clinical pharmacokinetics and use of infliximab [J].

Klotz, Ulrich ;

Teml, Alexander ;

Schwab, Matthias .

CLINICAL PHARMACOKINETICS, 2007, 46 (08) :645-660

[9] The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab [J].

Kopylov, U. ;

Mantzaris, G. J. ;

Katsanos, K. H. ;

Reenaers, C. ;

Ellul, P. ;

Rahier, J. F. ;

Israeli, E. ;

Lakatos, P. L. ;

Fiorino, G. ;

Cesarini, M. ;

Tsianos, E. V. ;

Louis, E. ;

Ben-Horin, S. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (03) :349-357

[10] Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease [J].

Maser, Elana A. ;

Villela, Renata ;

Silverberg, Mark S. ;

Greenberg, Gordon R. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (10) :1248-1254

← 1 2 →